with paroxetine. Prim Care Companion J Clin Psychiatry. 2005;7(4):202.
11. Keefer L, Palsson OS, Pandolfino JE. Best practice update: Incorporating psychogastroenterology into management of digestive disorders. Gastroenterology. 2018 Apr;154(5):1249–1257.
12. Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. J Clin Gastroenterol. 2014 Jul;48(6):505–512.
13. Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: A systematic review and meta-analysis. Gastroenterology. 2017;152(5):1042–1054.e1.
14. Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016; 151(6):1113–1121.
15. O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541–551.
16. Ormsbee HS 3rd, Fondacaro JD. Action of serotonin on the gastrointestinal tract. Proc Soc Exp Biol Med. 1985 Mar;178(3):333–338.
17. Palsson OS, Peery A, Seitzberg D, Amundsen ID, McConnell B, Simrén M. Human milk oligosaccharides support normal bowel function and improve symptoms of irritable bowel syndrome: A multicenter, open-label trial. Clin Transl Gastroenterol. 2020 Dec;11(12):e00276.
18. Palsson OS, Whitehead WE. Hormones and IBS. University of North Carolina Center for Functional and GI Motility Disorders website. https://www.med.unc.edu/ibs/wp-content/uploads/sites/450/2017/10/IBS-and-Hormones.pdf. Accessed December 12, 2021.
19. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32.
20. Schmick M, Hornecker J. Irritable bowel syndrome: A review of treatment options. US Pharm. 2017;42(12):20–26.
21. Su GL, Ko CW, Bercik P, et al. AGA Clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology. 2020;159(2):697–705.
22. Surdea-Blaga T, Baban A, Nedelcu L, Dumitrascu DL. Psychological interventions for irritable bowel syndrome. J Gastrointestin Liver Dis. 2016 Sep;25(3):359–366.
23. Vulevic J, Tzortzis G, Juric A, Gibson GR. Effect of a prebiotic galactooligosaccharide mixture (B-GOS®) on gastrointestinal symptoms in adults selected from a general population who suffer with bloating, abdominal pain, or flatulence. Neurogastroenterol Motil. 2018 Nov;30(11):e13440.
24. Vulevic J, Drakoularakou A, Yaqoob P, Tzortzis G, Gibson GR. Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. Am J Clin Nutr. 2008 Nov;88(5):1438–1446.
25. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581–1590.
26. Wilson B, Whelan K. Prebiotic inulin-type fructans and galacto-oligosaccharides: Definition, specificity, function, and application in gastrointestinal disorders. J Gastroenterol Hepatol. 2017 Mar;32 Suppl 1:64–68.
27. Zhou Q, Verne ML, Fields JZ, et al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019; 68:996–1002.
Глава 5
1. Gao KP, Mitsui T, Fujiki K, Ishiguro H, Kondo T. Effects of lactase preparations in asymptomatic individuals with lactase deficiency – gastric digestion of lactose and breath hydrogen analysis. J Med Sci. 2002;65(1–2):21–28.
2. Garcia-Etxebarria K, Zheng T, Bonfiglio F, et al. Increased prevalence of rare sucrase-isomaltase pathogenic variants in irritable bowel syndrome patients. Clin Gastroenterol Hepatol. 2018;16(10):1673–1676.
3. Gibson PR, Newnham E, Barrett JS, Shepherd SJ, Muir JG. Review article: Fructose malabsorption and the bigger picture. Aliment Pharmacol Ther. 2007;25(4):349–363.
4. Kim SB, Calmet FH, Garrido J, Garcia-Buitrago MT, Moshiree B. Sucrase-isomaltase deficiency as a potential masquerader in irritable bowel syndrome. Dig Dis Sci. 2020;65(2):534–540.
5. Komericki P, Akkilic-Materna M, Strimitzer T, Weyermair K, Hammer HF, Aberer W. Oral xylose isomerase decreases breath hydrogen excretion and improves gastrointestinal symptoms in fructose malabsorption – a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2012;36(10):980–987.
6. Levine B, Weisman S. Enzyme replacement as an effective treatment for the common symptoms of complex carbohydrate intolerance. Nutr Clin Care. 2004;7(2):75–81.
7. Lin MY, Dipalma JA, Martini MC, Gross CJ, Harlander SK, Savaiano DA. Comparative effects of exogenous lactase (beta-galactosidase) in preparations on in vivo lactose digestion. Dig Dis Sci. 1993; 38(11):2022–2027.
8. Robayo-Torres CC, Opekun AR, Quezada-Calvillo R, et al. 13C-breath tests for sucrose digestion in congenital sucrase isomaltase-deficient and sacrosidase-supplemented patients. J Pediatr Gastroenterol Nutr. 2009;48(4):412–418.
9. Sanders SW, Tolmac KG, Reitberg DP. Effect of a single dose of lactase on symptoms and expired hydrogen after lactose challenge in lactose-intolerant subjects. Clin Pharm. 1992;11(6):533–538.
Глава 6
1. Apte MV, Wilson JS, Korsten MA. Alcohol-related pancreatic damage: Mechanisms and treatment. Alcohol Health Res World. 1997;21(1):13–20.
2. Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16(24):2978–2990.
3. Camilleri M, Vijayvargiya P. The role of bile acids in chronic diarrhea. Am J Gastroenterol. 2020;115(10):1596–1603.
4. Camilleri M. Bile acid diarrhea: Prevalence, pathogenesis, and therapy. Gut Liver. 2015;9(3):332–339. doi:10.5009/gnl14397.
5. Chedid V, Dhalla S, Clarke JO, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014;3(3):16–24.
6. Choung RS, Ditah IC, Nadeau AM, et al. Trends and racial/ethnic disparities in gluten-sensitive problems in the United States: Findings from the National Health and Nutrition Examination surveys from 1988 to 2012. Am J Gastroenterol. 2015;110(3):455–461.
7. Gottlieb K, Wacher V, Sliman J, Pimentel M. Review article: Inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders. Aliment Pharmacol Ther. 2016;43(2):197–212.
8. Häuser W, Musial F, Caspary WF, Stein J, Stallmach A. Predictors of irritable bowel-type symptoms and healthcare-seeking behavior among adults with celiac disease. Psychosom Med. 2007;69(4):370–376.
9. Krigel A, Turner KO, Makharia GK, Green PH, Genta RM, Lebwohl B. Ethnic variations in duodenal villous atrophy consistent with celiac disease in the United States. Clin Gastroenterol Hepatol. 2016;14(8):1105–1111.
10. Leite GGS, Weitsman S, Parodi G, et al. Mapping the segmental microbiomes in the human small bowel in comparison with stool: A REIMAGINE study. Dig Dis Sci. 2020;65(9):2595–2604.
11. Meijer C, Shamir R, Szajewska H, Mearin L. Celiac disease prevention. Front Pediatr. 2018;6:368.
12. Monash University FODMAP Diet app. Version 3.0.8 (434). Monash University.
13. Muskal SM, Sliman J, Kokai-Kun J, Pimentel M, Wacher V, Gottlieb K. Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal
